ECSP045211A - Composiciones y métodos para la modulación de 'hemicanales de connexin' - Google Patents

Composiciones y métodos para la modulación de 'hemicanales de connexin'

Info

Publication number
ECSP045211A
ECSP045211A EC2004005211A ECSP045211A ECSP045211A EC SP045211 A ECSP045211 A EC SP045211A EC 2004005211 A EC2004005211 A EC 2004005211A EC SP045211 A ECSP045211 A EC SP045211A EC SP045211 A ECSP045211 A EC SP045211A
Authority
EC
Ecuador
Prior art keywords
compositions
methods
connexin
hemicanals
modulation
Prior art date
Application number
EC2004005211A
Other languages
English (en)
Inventor
Jorgen Soberg Petersen
Soren Neve
Morten Schak Nielsen
Eddi Meier
Eva Steiness
Peter Holme Jensen
Bjarne Due Larsen
Lars Bo Laurenborg Hansen
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP045211A publication Critical patent/ECSP045211A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/326—Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)

Abstract

El presente invento se relaciona en general con las composiciones y métodos para modular 'connexin hemichannels ' ( hemi-canales de conexión ). El invento también se relaciona con selectores que resultan útiles en la detección de tales compuestos.
EC2004005211A 2002-01-29 2004-07-29 Composiciones y métodos para la modulación de 'hemicanales de connexin' ECSP045211A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35271702P 2002-01-29 2002-01-29

Publications (1)

Publication Number Publication Date
ECSP045211A true ECSP045211A (es) 2004-09-28

Family

ID=27663122

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005211A ECSP045211A (es) 2002-01-29 2004-07-29 Composiciones y métodos para la modulación de 'hemicanales de connexin'

Country Status (15)

Country Link
US (2) US7153822B2 (es)
EP (1) EP1469875A1 (es)
JP (1) JP2005516054A (es)
KR (1) KR20040094677A (es)
CN (2) CN1638790A (es)
BR (1) BR0307279A (es)
CA (1) CA2474788A1 (es)
CO (1) CO5611159A2 (es)
EA (1) EA006860B1 (es)
EC (1) ECSP045211A (es)
HR (1) HRP20040784A2 (es)
MX (1) MXPA04007252A (es)
NO (1) NO20043590L (es)
WO (1) WO2003063891A1 (es)
ZA (1) ZA200405896B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20040784A2 (en) * 2002-01-29 2005-04-30 Wyeth Compositions and methods for modulating connexin hemichannels
DE10236528A1 (de) * 2002-08-09 2004-02-19 Bayer Ag Vorrichtung und Methoden zur Durchführung von elektrischen Messungen an Membrankörpern
DE10339597A1 (de) * 2003-08-26 2005-03-31 Bayer Technology Services Gmbh Vorrichtung und Verfahren zum Nachweis biochemischer Aktivität enthaltend Gap Junctions
CA2550632A1 (en) * 2003-12-23 2005-07-07 Bjarne Due Larsen Isopeptide gap junction modulators
DK1959981T3 (da) 2005-02-03 2020-01-27 Coda Therapeutics Ltd Anti-connexin 43 forbindelser til behandling af kroniske sår
GB0514071D0 (en) * 2005-07-07 2005-08-17 Zealand Pharma As N- or C- terminally modified small peptides
EP2091557A2 (en) 2006-11-15 2009-08-26 Coda Therapeutics, INC. Improved methods and compositions for wound healing
CN101835476B (zh) 2006-12-11 2016-08-17 科达治疗公司 作为受损伤口愈合组合物的抗连接蛋白多核苷酸
WO2008079412A2 (en) * 2006-12-22 2008-07-03 The Trustees Of Columbia University In The City Of New York Methods and compositions to treat arrhythmias
US20100298225A1 (en) * 2007-07-15 2010-11-25 Bjarne Due Larsen Peptide gap junction modulators
US20110091485A1 (en) * 2007-08-06 2011-04-21 Carter William G Modulation of cell junctions
US20110300130A1 (en) * 2007-12-11 2011-12-08 Becker David L Impaired wound healing compositions and treatments
EP2245158A2 (en) * 2007-12-11 2010-11-03 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US8975237B2 (en) 2007-12-21 2015-03-10 Coda Therapeutics, Inc. Treatment of fibrotic conditions
JP2011507599A (ja) 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 改良医療デバイス
JP2011507861A (ja) * 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 線維症性の状態の治療のための抗コネキシンポリヌクレオチド剤と組み合わせた抗コネキシンポリペプチド剤の使用
CA2710375A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of orthopedic conditions
US20110144182A1 (en) * 2007-12-21 2011-06-16 David Lawrence Becker Treatment of surgical adhesions
US20110038920A1 (en) * 2008-01-07 2011-02-17 Ryoichi Mori Wound healing compositions and treatments
RU2457862C1 (ru) * 2011-07-07 2012-08-10 Федеральное государственное учреждение "Государственный научный центр социальной и судебной психиатрии им. В.П. Сербского" Министерства здравоохранения и социального развития Российской Федерации Способ лечения низкодифференцированных глиом
CA2921652A1 (en) * 2013-08-21 2015-02-26 Manuel A. Riquelme Compositions and methods for targeting connexin hemichannels
US10465188B2 (en) 2014-08-22 2019-11-05 Auckland Uniservices Limited Channel modulators
EP3419998A4 (en) 2016-02-26 2019-09-25 The Board of Regents of The University of Texas System CONNEXIN (CX) 43 HEMICANAL BINDING ANTIBODIES AND USES THEREOF
US11433116B2 (en) 2016-04-14 2022-09-06 Cedars-Sinai Medical Center GJA1 isoforms protect against metabolic stress
CN111201247A (zh) 2017-04-28 2020-05-26 奥克兰联合服务有限公司 治疗方法和新颖构建体
CA3070089A1 (en) 2017-07-19 2019-01-24 Auckland Uniservices Limited Cytokine modulation
JP7795359B2 (ja) * 2019-04-23 2026-01-07 オキュネクシス セラピューティクス， インコーポレイテッド 上皮および関門の完全性を保護するための組成物および方法

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US59608A (en) * 1866-11-13 Improved drill or well tube
US107308A (en) * 1870-09-13 Improvement in safety-valvs
US3740438A (en) 1971-05-27 1973-06-19 Stanley Drug Products Inc Methods and compositions for inducing resistance to bacterial infections using certain lysine derivatives
CH577464A5 (es) 1972-09-22 1976-07-15 Ciba Geigy Ag
US4725582A (en) 1978-11-14 1988-02-16 Fujisawa Pharmaceutical Company, Ltd. Peptide, process for preparation thereof and use thereof
US4340592A (en) 1980-03-14 1982-07-20 Adibi Siamak A Nutrient compositions and method of administering the same
US4636492A (en) 1984-08-29 1987-01-13 E. I. Du Pont De Nemours And Company Inhibition of viral protease activity by peptide halomethyl ketones
US4652552A (en) 1984-09-10 1987-03-24 E. I. Du Pont De Nemours And Company Tetrapeptide methyl ketone inhibitors of viral proteases
US5047401A (en) 1985-09-09 1991-09-10 Board Of Regents, The University Of Texas System Use of dipeptide alkyl esters to treat GVHD
DE3544338A1 (de) 1985-12-14 1987-06-19 Hoechst Ag Peptid-derivate mit inhibitorischer wirkung auf hydroxylierende enzyme, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
EP0254032A3 (en) 1986-06-20 1990-09-05 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
SE8702550D0 (sv) 1987-06-18 1987-06-18 Anders Grubb Cysteinproteashemmare
US5223486A (en) 1988-11-01 1993-06-29 University Research Corporation Inhibition of cancer procoagulant
US5965695A (en) 1990-05-15 1999-10-12 Chiron Corporation Modified peptide and peptide libraries with protease resistance, derivatives thereof and methods of producing and screening such
US5637618A (en) 1990-06-01 1997-06-10 Bioresearch, Inc. Specific eatable taste modifiers
DE4022267C2 (de) 1990-07-12 1994-09-15 Degussa N-Acyldipeptide und deren Verwendung
ATE174343T1 (de) 1991-02-27 1998-12-15 Lacer Sa Antihypertensive n-(alpha-substituiertes pyridyl)-carbonyldipeptide
US5492894A (en) 1991-03-21 1996-02-20 The Procter & Gamble Company Compositions for treating wrinkles comprising a peptide
EP0520573A1 (en) 1991-06-27 1992-12-30 Glaxo Inc. Cyclic imide derivatives
DE4122885A1 (de) 1991-07-11 1993-01-21 Hoechst Ag Verfahren zur diastereoselektiven reduktiven pinakol-kupplung von homochiralen (alpha)-aminoaldehyden
AU657701B2 (en) 1991-08-30 1995-03-23 Vertex Pharmaceuticals Incorporated Interleukin 1beta protease and interleukin 1beta protease inhibitors
US5650508A (en) 1991-12-27 1997-07-22 Georgia Tech Research Corporation Peptide ketoamides
US6235929B1 (en) 1991-12-27 2001-05-22 Georgia Tech Research Corporation Tripeptide α-ketoamides
AU3479593A (en) 1992-01-31 1993-09-01 Merck & Co., Inc. Peptidyl derivatives as inhibitors of interleukin-1beta converting enzyme
US5602102A (en) 1992-05-29 1997-02-11 Board Of Regents, The Univ. Of Tx System Dipeptidyl peptidase-I inhibitors and uses thereof
FR2694559B1 (fr) 1992-08-06 1994-10-28 Atta Nouveaux dérivés amphiphiles d'aminoacides ou de peptides, leur procédé de préparation et leur utilisation dans des préparations à usage biomédical.
US5514694A (en) 1992-09-21 1996-05-07 Georgia Tech Research Corp Peptidyl ketoamides
JPH08504194A (ja) 1992-12-01 1996-05-07 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプターアンタゴニスト
IL107719A0 (en) 1992-12-21 1994-02-27 Du Pont Imidazolones their manufacture and their use as herbicides
WO1994015908A1 (fr) 1993-01-14 1994-07-21 Yoshitomi Pharmaceutical Industries, Ltd. Derive de propionamide et son utilisation medicinale
DE4311021A1 (de) 1993-03-31 1994-10-27 Diagnostikforschung Inst Bifunktionelle Chelatbildner, deren Technetium- und Rhenium-Komplexe, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende radiopharmazeutische Mittel
DE4314260A1 (de) 1993-04-30 1994-11-03 Hoechst Ag Peptide zur Behandlung von Hypoglykämie, Verfahren zu ihrer Herstellung und ihre Verwendung
US20040167106A1 (en) 1993-06-04 2004-08-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of a Vitamin D compound
US6342481B1 (en) 1993-10-12 2002-01-29 Italfarmaco S.P.A. Oligopeptides derived from C-reactive protein fragments
US5492920A (en) 1993-12-10 1996-02-20 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5492916A (en) 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5494919A (en) 1993-11-09 1996-02-27 Merck & Co., Inc. 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
KR960705808A (ko) 1993-11-09 1996-11-08 조셉 에프. 디프리마 성장 호르몬의 방출을 촉진시키는 피페리딘, 피롤리딘 및 헥사하이드로-1H-아제핀(Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone)
WO1995017204A1 (en) 1993-12-23 1995-06-29 Auckland Uniservices Limited Composition and methods to improve neural outcome
GB9425582D0 (en) 1994-12-19 1995-02-15 Iaf Biochem Int Peptides having immunomodulatory activity
US5863902A (en) 1995-01-06 1999-01-26 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
DE19500990A1 (de) * 1995-01-14 1996-07-18 Stefan Dr Med Dhein Neues Peptid, seine Herstellung und Verwendung
CA2215211A1 (en) 1995-03-31 1996-10-03 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
US5798442A (en) 1995-04-21 1998-08-25 Merck Frosst Canada, Inc. Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases
US5849711A (en) 1995-06-06 1998-12-15 Athena Neurosciences, Inc. Cathepsin and methods and compositions for inhibition thereof
JPH11508452A (ja) 1995-07-11 1999-07-27 デグッサ アクチエンゲゼルシャフト ペプチドおよびｎ−カルバモイル保護されたペプチドの新規製造法
WO1997005889A1 (en) 1995-08-03 1997-02-20 Slesarev Vladimir I Non-specific vaccination by d-amino-acid containing compounds
EP0866718A1 (en) * 1995-12-13 1998-09-30 President And Fellows Of Harvard College Use of toxin peptides and/or affinity handles for the delivering compounds into cells
US5877182A (en) 1996-09-13 1999-03-02 Merck & Co., Inc. Piperidines promote release of growth hormone
WO1998010653A1 (en) 1996-09-13 1998-03-19 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
US6191166B1 (en) 1997-11-21 2001-02-20 Elan Pharmaceuticals, Inc. Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
ATE261988T1 (de) 1996-12-27 2004-04-15 Boehringer Ingelheim Ca Ltd Peptidomimetische inhibitoren von der protease des menschlichen cytomegalovirus
US6017925A (en) 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
JP2001509176A (ja) 1997-01-17 2001-07-10 メルク エンド カンパニー インコーポレーテッド インテグリンアンタゴニスト
US6187906B1 (en) 1997-08-11 2001-02-13 Aukland Uniservices Limited Methods to improve neural outcome
TW460478B (en) 1997-08-15 2001-10-21 Chugai Pharmaceutical Co Ltd Phenethylamine derivatives
US6410585B1 (en) 1997-08-28 2002-06-25 Scott D. Larsen Inhibitors of protein tyrosine phosphatase
EP1019364B1 (en) 1997-08-28 2004-06-09 Biovitrum Ab Inhibitors of protein tyrosine phosphatase
US6150378A (en) 1997-10-07 2000-11-21 Cephalon, Inc. Peptidyl-containing α-ketoamide cysteine and serine protease inhibitors
GB9726569D0 (en) 1997-12-16 1998-02-11 Univ Southampton Neuroprotective agents
DE19816932A1 (de) 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue Peptide, Verfahren zu ihrer Herstellung und diese Peptide enthaltende pharmazeutische Zusammensetzungen
ATE212642T1 (de) 1998-06-05 2002-02-15 Aventis Pharma Sa Verfahren zur herstellung von aspartyl- cyclohexylalaninamid
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US20030176357A1 (en) 1998-10-06 2003-09-18 Pospisilik Andrew J. Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
TR200101663T2 (tr) 1998-12-10 2001-11-21 F.Hoffmann-La Roche Ag Pro-kollajen c-proteinaz inhibitörleri
HK1039110A1 (zh) 1999-03-15 2002-04-12 Axys Pharmaceuticals, Inc. 以新颖的合成物及组分作为蛋白酶抑制剂
IL146892A0 (en) 1999-06-03 2002-08-14 Ca Nat Research Council 3-dimensional in vitro models of mammalian tissue
DK1194425T3 (da) 1999-06-23 2005-11-21 Aventis Pharma Gmbh Substituerede benzimidazoler
JP2003520266A (ja) 2000-01-24 2003-07-02 メルク シャープ エンド ドーム リミテッド γ−セクレターゼ阻害薬
DE60107803T2 (de) * 2000-02-23 2006-01-19 Zealand Pharma A/S Neue antiarrythmische peptide
US7585839B2 (en) * 2000-02-23 2009-09-08 Zealand Pharma A/S Medical uses of intercellular communication facilitating compounds
US7250397B2 (en) * 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
WO2001092236A1 (de) 2000-05-26 2001-12-06 Basf Aktiengesellschaft 4-halogenalkyltriazinverbindungen als herbizide
WO2001090085A2 (de) 2000-05-26 2001-11-29 Basf Aktiengesellschaft 6-methyl-4-trihalogenmethyltriazinverbindungen
BR0111718A (pt) 2000-06-16 2003-09-09 Hercules Inc Peptìdeos quimicamente modificados, composições e métodos de produção e uso
US7498297B2 (en) 2000-07-18 2009-03-03 Cornell Research Foundation Medicinal uses of mu-opioid receptor agonists
JP2005506295A (ja) 2001-02-22 2005-03-03 ジーランド ファーマ アクティーゼルスカブ 細胞間連絡促進化合物の新規医薬使用
GB0107924D0 (en) 2001-03-29 2001-05-23 Angeletti P Ist Richerche Bio Inhibitor of hepatitis C virus NS3 protease
US20030236198A1 (en) 2001-06-13 2003-12-25 Genesoft, Inc. Antipathogenic benzamide compounds
IL159321A0 (en) * 2001-06-15 2004-06-01 Ca Nat Research Council Methods for modulating intercellular gap junctions
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
US20030135023A1 (en) 2001-06-27 2003-07-17 Hans-Ulrich Demuth Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis
AU2002331064B2 (en) 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
WO2003032964A2 (en) * 2001-10-17 2003-04-24 University Of Wales College Of Medecine Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
US20030194445A1 (en) 2001-11-12 2003-10-16 Kuhner Carla H. Compositions and methods of use of peptides in combination with biocides and/or germicides
FI20012242A0 (fi) 2001-11-19 2001-11-19 Orion Corp Uudet farmaseuttiset yhdisteet
EP1478328B1 (en) 2002-01-28 2013-06-05 Keraplast Technologies Ltd. Bioactive keratin peptides
HRP20040784A2 (en) * 2002-01-29 2005-04-30 Wyeth Compositions and methods for modulating connexin hemichannels
US20040005304A1 (en) 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
US20040121964A1 (en) 2002-09-19 2004-06-24 Madar David J. Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
EP1553964A4 (en) 2002-09-25 2009-08-12 Georgia Tech Res Inst KETOAMID INHIBITORS IN CHRONIC NERVE DISEASES
US20060194947A1 (en) 2002-11-25 2006-08-31 Larsen Bjarne D Peptide gap junction modulators

Also Published As

Publication number Publication date
CN1638790A (zh) 2005-07-13
NO20043590L (no) 2004-08-27
CN1939529A (zh) 2007-04-04
CO5611159A2 (es) 2006-02-28
HRP20040784A2 (en) 2005-04-30
EA200400984A1 (ru) 2005-02-24
EP1469875A1 (en) 2004-10-27
EA006860B1 (ru) 2006-04-28
MXPA04007252A (es) 2005-03-31
ZA200405896B (en) 2006-07-26
WO2003063891A1 (en) 2003-08-07
CA2474788A1 (en) 2003-08-07
JP2005516054A (ja) 2005-06-02
BR0307279A (pt) 2004-12-28
KR20040094677A (ko) 2004-11-10
US20040092429A1 (en) 2004-05-13
US7153822B2 (en) 2006-12-26
US20070042964A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
ECSP045211A (es) Composiciones y métodos para la modulación de 'hemicanales de connexin'
GT200900264A (es) Moléculas y métodos para modular la pro-proteina
ECSP095220A (es) Derivados de n-fenil-2-pirimidin-amina
MA28985B1 (fr) Analogues de loxapine et methodes d'utilisation
BRPI9915679B8 (pt) composições e métodos para aumentar a mineralização óssea
TW200719892A (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
GT200500179BA (es) Mezclas sinergistas de agentes de antranilamida para el control de plagas de invertebrados
BRPI0411528A (pt) uso de isomalte como prebiótico
BRPI0413363A (pt) formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
EP1276491A4 (en) TAMANDARINE AND DIDEMNIN ANALOGA AND METHODS FOR THEIR PRODUCTION AND USE
MX2007013065A (es) Derivados de dihidrobenzofurano y usos de los mismos.
CR8926A (es) Acidos de tiazolo-naftilo
DE60320784D1 (de) Stände zur modulierung des knochenwachstums
EP1931772A4 (en) MUTANT REVERSE TRANSCRIPTASE AND USE METHOD
ATE382060T1 (de) Moleküle und verfahren zur inhibierung der freisetzung von kim-1
JO2369B1 (en) Novel cyclohexyl sulphones
ECSP088242A (es) Combinaciones que comprenden dmxaa para el tratamiento de cancer
ATE522223T1 (de) Pflanzenextrakte
DE69934325D1 (de) Zusammenstellungen zur erhöhung der darmabsoption von fetten
BRPI0603197A (pt) composição de toner
NO955288L (no) Skvalen-syntetase inhibitorer
EP1572168A4 (en) ANTI-INFARCTION MOLECULES
WO2003103709A3 (en) Cd200-receptor mediated modulation of bone development
TR200400941T4 (tr) Lipid kinazların modülatörlerinin taranması için yöntemler ve bileşimler
AU2003222426A1 (en) Methods and compositions for modulating beta-catenin phosphorylation